Category - Executive Moves

Executive Moves

Candel appoints Mark Sims as CCO

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of Mark Sims as its chief commercial officer (CCO), effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for...

June 25, 2026

Executive Moves

E.F. Hutton appoints healthcare investment banking veteran Bryan Kobel as managing director

Global investment bank E.F. Hutton & Co. has announced the appointment of former public company CEO Bryan Kobel as managing director. Mr. Kobel rejoins E.F. Hutton, where he previously served as managing director...

June 15, 2026

Executive Moves

Dr. Jeff Coller joins 4basebio’s SAB

4basebio (AIM: 4BB) has appointed Jeff Coller, PhD, to its strategic advisory board (SAB). Dr. Coller is a globally recognized expert in mRNA biology and translation. According to 4basebio, his understanding of...

June 15, 2026

Executive Moves

Tempest appoints Drake Richey and Dr. John Yee to BoD

Tempest Therapeutics (NASDAQ: TPST) has appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its board of directors (BoD), effective June 4, 2026. Mr. Richey and Dr. Yee collectively bring decades...

June 5, 2026

Executive Moves

Cocrystal appoints James Sapirstein as CEO

Cocrystal Pharma (NASDAQ: COCP) has appointed biopharma industry leader James Sapirstein as chief executive officer (CEO), effective immediately. According to Cocrystal, Mr. Sapirstein will also be appointed to its...

June 4, 2026

Executive Moves

Dr. John Lambert joins Defence BoD

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. John Lambert to its board of directors (BoD), effective immediately. Internationally recognized, Dr. Lambert brings more than four decades of...

June 1, 2026

Executive Moves

Former FDA official Peter J. Pitts joins BrainStorm BoD

BrainStorm Cell Therapeutics (OTCQB: BCLI) has appointed former FDA associate commissioner, Peter J. Pitts, to its board of directors (BoD), effective immediately. Mr. Pitts is a globally recognized expert in healthcare...

May 28, 2026

Executive Moves

Immunic appoints Michael W. Bonney as BoD chair

Immunic (NASDAQ: IMUX) has announced the appointment of biopharmaceutical executive Michael W. Bonney as chair of its board of directors (BoD), effective May 16, 2026. Simona Skerjanec, MPharm, MBA, will transition from...

May 19, 2026

Executive Moves

ARS appoints Donn Casale as president

ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as president, effective June 1, 2026, with Richard Lowenthal continuing to lead as CEO. Mr. Casale brings 25 years of biopharmaceutical commercial leadership...

May 13, 2026

Executive Moves

BetterLife appoints Doug Drysdale as executive chairman and director

BetterLife Pharma (CSE: BETR; OTCQB: BETRF; FSE: NPAU) has appointed its current corporate advisor, Doug Drysdale, as executive chairman and director. Mr. Drysdale was formerly CEO of Cybin (NYSE: CYBN) where he led the...

May 13, 2026

Category - Executive Moves

Subscribe